CYD vs ZEPP
China Yuchai International Limited and Zepp Health Corp., side by side — 10 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CYD | ZEPP |
|---|---|---|
| Revenue | ¥19.1B | ¥258.9M |
| Net income | ¥323.1M | ¥-40.1M |
| Gross margin | 14.7% | 38.3% |
| Net margin | 1.7% | −15.5% |
| Return on equity | 3.5% | −17.2% |
| Diluted EPS | ¥8.21 | — |
| Dividend / share | ¥0.38 | — |
| Payout ratio | 31.5% | −14.6% |
| Free cash flow | ¥419.2M | ¥-26.2M |
| Equity | ¥9.2B | ¥214.5M |
| Net debt / equity | 0.08× | 0.01× |
| Current ratio | 1.55× | 1.02× |
| Revenue CAGR 5y | 1.2% | −47.4% |
| Profit CAGR 5y | −11.8% | — |
CYD bills 73.9× the revenue of ZEPP, and ZEPP closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | CYD | ZEPP |
|---|---|---|
| FY2024 | ¥19.1B | ¥182.6M |
| FY2023 | ¥18.0B | ¥352.9M |
| FY2022 | ¥16.0B | ¥613.6M |
| FY2021 | ¥21.3B | ¥6.3B |
| FY2020 | ¥20.6B | ¥6.4B |
| FY2019 | ¥18.0B | ¥5.8B |
| FY2018 | ¥16.3B | ¥3.6B |
| FY2017 | ¥16.2B | ¥2.0B |
| FY2016 | ¥13.6B | ¥1.6B |
| FY2015 | ¥13.7B | ¥896.5M |
Net income by year
Bottom line
| Fiscal year | CYD | ZEPP |
|---|---|---|
| FY2024 | ¥323.1M | ¥-75.7M |
| FY2023 | ¥285.5M | ¥-31.0M |
| FY2022 | ¥218.6M | ¥-43.2M |
| FY2021 | ¥272.7M | ¥137.8M |
| FY2020 | ¥548.9M | ¥228.8M |
| FY2019 | ¥604.9M | ¥575.2M |
| FY2018 | ¥695.3M | ¥340.0M |
| FY2017 | ¥888.8M | ¥167.7M |
| FY2016 | ¥525.2M | ¥23.9M |
| FY2015 | ¥341.1M | ¥-37.9M |
Advertisement
AdSense · Rectangle 336×280
More in this industry